CiMaas

Description

CiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications to treat cancers including breast and pancreatic tumors.

CiMaas is located in the Netherlands ecosystem.

Related

• ONK TherapeuticsONK Therapeutics develops off-the-shelf, optimally engineered natural killer (NK) cell therapies combining CAR and TRAIL variant constructs…
• Ability PharmaceuticalsAbility Pharmaceuticals develops oral targeted anticancer compounds that induce selective autophagy-mediated cytotoxicity in cancer cells;…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
• OncolinesOncolines provides precision medicine services in oncology and cancer immunotherapy, offering cell‑based assays, profiling platforms,…
• Mosa MeatMosa Meat grows real beef burgers by taking a sesame-seed-sized cell sample and nurturing cells through natural muscle-growth processes,…
• NeoPhoreNeoPhore develops small-molecule cancer therapeutics that briefly inhibit DNA mismatch repair, shifting MMR-proficient tumors toward an…
• CollimateHealthCollimateHealth develops microbeam radiation systems that deliver arrays of extremely narrow radiation beams to treat tumors while sparing…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…